Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v3.24.1.u1
Segment Information
9 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Segment Information

Note 13. Segment Information:

The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with the impact of partially-owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics segments both include consumables, instruments, services and royalty revenue.

The following is financial information relating to the Company's reportable segments (in thousands):

Quarter Ended

Nine Months Ended

March 31, 

March 31, 

    

2024

    

2023

2024

    

2023

Net sales:

 

  

  

Protein Sciences

$

214,589

  

$

218,903

$

616,914

  

$

622,739

Diagnostics and Genomics

 

87,511

 

75,669

 

235,715

 

213,577

Other revenue(1)

2,093

2,093

Intersegment

 

(765)

 

(426)

 

(1,761)

 

(934)

Consolidated net sales

$

303,428

  

$

294,146

$

852,961

  

$

835,382

Operating income:

 

  

 

  

 

  

 

  

Protein Sciences

$

94,829

  

$

98,756

$

262,777

  

$

274,035

Diagnostics and Genomics

 

8,104

 

11,464

 

13,189

 

28,399

Segment operating income

$

102,933

$

110,220

$

275,966

$

302,434

Costs recognized on sale of acquired inventory

 

(186)

 

 

(550)

 

(400)

Amortization of intangibles

 

(19,287)

 

(19,286)

 

(58,908)

 

(57,694)

Impact of partially-owned consolidated subsidiaries(2)

 

 

 

 

647

Acquisition related expenses and other

 

(3,286)

 

1,333

 

(2,173)

 

9,343

Impairment of assets held-for-sale

(6,038)

Stock based compensation, inclusive of employer taxes

 

(8,358)

 

(10,543)

 

(32,810)

 

(42,879)

Restructuring and restructuring-related costs

 

(1,550)

 

 

(7,157)

 

(2,950)

Corporate general, selling, and administrative expenses

 

(3,346)

 

(1,513)

 

(7,545)

 

(4,082)

Impact of business held-for-sale(1)

78

78

Consolidated operating income

$

66,998

  

$

80,211

$

160,863

  

$

204,419

(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.

(2) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.